Gilead Attacks Post-Merger Claim to $50M Cancer Drug Bonus
By Jeff Montgomery ( September 13, 2016, 9:20 PM EDT) -- Attorneys for Gilead Sciences Inc. pressed former Calistoga Pharmaceuticals Inc. officials Tuesday at trial in Delaware's Chancery Court to defend a $50 million post-merger bonus demand for Calistoga's stockholders filed after their former company's cancer drug won a limited-use approval....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.